Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.20.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Operating expenses:        
Research and development $ 4,910,827 $ 1,643,659 $ 15,555,725 $ 4,950,457
General and administrative 8,165,488 3,841,189 32,628,919 14,380,898
Depreciation and amortization 23,869 18,510 67,092 36,424
Total operating expenses 13,100,184 5,503,358 48,251,736 19,367,779
Loss from operations (13,100,184) (5,503,358) (48,251,736) (19,367,779)
Other income (expense):        
Interest income, net 1,743 39,354 44,773 84,623
Loss on foreign currency translation 0 0 (1,161) 0
Loss before income taxes (13,098,441) (5,464,004) (48,208,124) (19,283,156)
Income taxes (benefit) 0 0 0 0
Net loss (13,098,441) (5,464,004) (48,208,124) (19,283,156)
Non-controlling interest 1,696,582 20,538 6,282,420 20,538
Net loss attributable to BioSig Technologies, Inc. (11,401,859) (5,443,466) (41,925,704) (19,262,618)
Preferred stock dividend (2,381) (4,877) (11,698) (20,286)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS $ (11,404,240) $ (5,448,343) $ (41,937,402) $ (19,282,904)
Net loss per common share, basic and diluted (in Dollars per share) $ (0.38) $ (0.25) $ (1.56) $ (0.96)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 29,750,378 21,809,998 26,900,383 20,124,322